千紅製藥(002550.SZ):目前進展最快的新藥項目QHRD107(適應症為復發難治急性髓系白血病),預計於年底取得階段性進展
格隆匯5月9日丨千紅製藥(002550.SZ)於2024年5月9日召開業績説明會,就“公司提到有創新藥進入或即將進入二期臨牀試驗,能否詳細介紹一下這些新藥的研發進展、市場潛力以及預期上市時間?這些新藥的研發對公司的未來發展具有怎樣的戰略意義?”,公司回覆稱,公司目前進展最快的新藥項目QHRD107(適應症為復發難治急性髓系白血病),是一款CDK9激酶抑制劑類小分子一類新藥,已完成IIa期臨牀爬坡實驗且獲得了令人鼓舞的初步結果,預計於年底取得階段性進展。另一款大分子一類新藥QHRD106(適應症為急性缺血性腦卒中),是一款通過長效促進腦血管循環、穩定釋放活性蛋白以改善腦卒中愈後治療的藥物,市場需求廣泛,已於日前開展II期臨牀方案討論會並獲國家新藥評審中心無保留通過,後期將開展上百例的病例入組試驗。
此外,公司還有在研小分子抗腫瘤新藥QHRD110(首選適應症為腦膠質瘤)已完成澳洲I期臨牀;QHRD211(適應症為生長激素缺少的兒童生長緩慢)也已完成I期臨牀試驗進入II期臨牀試驗。在不久的將來,公司定會實現從傳統生物醫藥領域邁向創新藥物領域的跨越式發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.